Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $4.66B | $4.03B | +15.60% |
Cost of Revenue | $1.86B | $1.59B | +16.64% |
Gross Profit | $2.8B | $2.44B | +14.92% |
Operating Income | $911.8M | $600M | +51.97% |
Net Income | $836.3M | $576.2M | +45.14% |
EPS (Basic) | $2.14 | $1.46 | +46.58% |
EPS (Diluted) | $2.09 | $1.42 | +47.18% |
R&D Expense | $599.1M | $552.4M | +8.45% |
SG&A Expense | $1.29B | $1.29B | +0.40% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $6.34B | $6.48B | -2.23% |
Current Assets | $4.03B | $4.3B | -6.23% |
Total Liabilities | $3.59B | $4.38B | -17.98% |
Current Liabilities | $2.14B | $2.93B | -26.93% |
Stockholders' Equity | $2.75B | $2.1B | +30.60% |
Cash & Equivalents | $917.7M | $606.1M | +51.41% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.44B | $989.5M | +45.60% |
Investing Cash Flow | $536M | $-207.5M | +358.31% |
Financing Cash Flow | $-1.69B | $-734.8M | -129.50% |
Share Buybacks | $500M | $750M | -33.33% |
D&A | $251.8M | $217.7M | +15.66% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 60.1% | 60.5% | -0.36% |
Operating Margin | 19.6% | 14.9% | +4.68% |
Net Margin | 17.9% | — | — |
ROE | 30.5% | — | — |
ROA | 13.2% | — | — |
Current Ratio | $1.883 | — | — |
Debt to Equity | $1.309 | — | — |
DXCM reported strong financial performance in 2025 with significant growth in revenue and net income, driven by operational efficiencies and strategic investments.
DXCM achieved a 15.6% increase in revenue, driven by increased market penetration and product innovation.
Source: Source: 10-K Income Statement, p.1
Operating income increased by 52.0%, reflecting improved operational efficiencies and cost management.
Source: Source: 10-K Income Statement, p.1
Operating cash flow increased by 45.6%, indicating strong cash generation from core operations.
Source: Source: 10-K Cash Flow Statement, p.1
DXCM faces intense competition in the medical device industry, which could impact market share and pricing power.
Source: Source: Industry Analysis
Unlock 2 more detailed risk analysis